PC
IOVA icon

PA Capital’s Iovance Biotherapeutics IOVA Stock Holding History

PA Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$260K Sell
7,899
-6,133
-44% -$188K 0.18% 146
2020
Q2 		$385K Sell
14,032
-25,290
-64% -$831K 0.28% 113
2020
Q1 		$1.18M Buy
39,322
+15,028
+62% +$398K 1.04% 24
2019
Q4 		$672K Buy
24,294
+3,081
+15% +$70.1K 0.59% 67
2019
Q3 		$386K Sell
21,213
-1,690
-7% -$37.4K 0.38% 89
2019
Q2 		$562K Sell
22,903
-29,056
-56% -$438K 0.51% 67
2019
Q1 		$494K Sell
51,959
-5,765
-10% -$56K 0.44% 69
2018
Q4 		$511K Buy
+57,724
New +$557K 0.54% 64

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

PA Capital's IOVA Position: Q3 2020 in Review

PA Capital reduced its Iovance Biotherapeutics (IOVA) stake by 44% in Q3 2020, selling an estimated $188K and leaving 7,899 shares worth $260K. The position accounts for 0.18% of the portfolio, ranked #146.

PA Capital first reported a position in IOVA in Q4 2018 and has held it in 8 quarters since. The position peaked at $1.18M in Q1 2020. 252 funds tracked by Wall St. Rank hold IOVA as of Q3 2020.

  • PA Capital held 7,899 shares of Iovance Biotherapeutics worth $260K as of Q3 2020.
  • PA Capital sold 6,133 Iovance Biotherapeutics shares in Q3 2020, an estimated $188K.
  • Iovance Biotherapeutics made up 0.18% of PA Capital's portfolio in Q3 2020, its #146 holding.
  • PA Capital first reported a position in Iovance Biotherapeutics in Q4 2018 and has held it in 8 quarters since.
  • PA Capital's Iovance Biotherapeutics position peaked at $1.18M in Q1 2020.
  • 252 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2020.

Based on PA Capital's 13F filing for Q3 2020, filed 13 Nov 2020.